Automated production of [18F]Flortaucipir for PET imaging of tauopathies

• Published in: American journal of nuclear medicine and molecular imaging 2021-01, Vol.11 (3), p.167-177
• Main Authors: Jiang, Huailei, Jain, Manoj K, Cai, Hancheng
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2160-8407; 2160-8407

Radiotracer [ 18 F]Flortaucipir is an FDA-approved diagnostic agent for PET imaging of density and distribution of abnormal tau protein deposition (tauopathies) in Alzheimer’s disease. A high-yield automated method for routine GMP-compliant [ 18 F]Flortaucipir production is desired to meet increasing clinical need. In this work, we reported an automated radiosynthesis of [ 18 F]Flortaucipir in a RNplus Research module and the quality control (QC) tests for human use under full GMP compliance. Briefly, automated radiosynthesis of [ 18 F]Flortaucipir was processed via nucleophilic radiofluorination of precursor AV1622 and followed by acid hydrolysis in a RNplus Research module, which included the radiosynthesis, semi-preparative high-performance liquid chromatography (HPLC) purification, and the final formulation via solid phase extraction (SPE). The final products were obtained in non-decay corrected radiochemical yields of 14.8-16.6% (n = 3) within total synthesis time of 55 min. The radiochemical purities of [ 18 F]Flortaucipir were > 99.9% and the molar activities were 247.9-384.8 GBq/µmol at end of synthesis. The results of QC tests met all the specifications for human use. In conclusion, [ 18 F]Flortaucipir was reproducibly achieved with desired radiochemical yield and high radiochemical purity and molar activity. Three GMP compliant validation runs and QC results demonstrated the efficacy of this method for automated production of [ 18 F]Flortaucipir for human use.